248 related articles for article (PubMed ID: 38167338)
1. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response.
Zhao M; Wang T; Gleber-Netto FO; Chen Z; McGrail DJ; Gomez JA; Ju W; Gadhikar MA; Ma W; Shen L; Wang Q; Tang X; Pathak S; Raso MG; Burks JK; Lin SY; Wang J; Multani AS; Pickering CR; Chen J; Myers JN; Zhou G
Nat Commun; 2024 Jan; 15(1):180. PubMed ID: 38167338
[TBL] [Abstract][Full Text] [Related]
2. Gain-of-function mutant p53 in cancer progression and therapy.
Zhang C; Liu J; Xu D; Zhang T; Hu W; Feng Z
J Mol Cell Biol; 2020 Sep; 12(9):674-687. PubMed ID: 32722796
[TBL] [Abstract][Full Text] [Related]
3. p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression.
Ghosh M; Saha S; Li J; Montrose DC; Martinez LA
Mol Cell; 2023 Jan; 83(2):266-280.e6. PubMed ID: 36638783
[TBL] [Abstract][Full Text] [Related]
4. Chromosomal instability drives metastasis through a cytosolic DNA response.
Bakhoum SF; Ngo B; Laughney AM; Cavallo JA; Murphy CJ; Ly P; Shah P; Sriram RK; Watkins TBK; Taunk NK; Duran M; Pauli C; Shaw C; Chadalavada K; Rajasekhar VK; Genovese G; Venkatesan S; Birkbak NJ; McGranahan N; Lundquist M; LaPlant Q; Healey JH; Elemento O; Chung CH; Lee NY; Imielenski M; Nanjangud G; Pe'er D; Cleveland DW; Powell SN; Lammerding J; Swanton C; Cantley LC
Nature; 2018 Jan; 553(7689):467-472. PubMed ID: 29342134
[TBL] [Abstract][Full Text] [Related]
5. Targeting codon 158 p53-mutant cancers via the induction of p53 acetylation.
Kong LR; Ong RW; Tan TZ; Mohamed Salleh NAB; Thangavelu M; Chan JV; Koh LYJ; Periyasamy G; Lau JA; Le TBU; Wang L; Lee M; Kannan S; Verma CS; Lim CM; Chng WJ; Lane DP; Venkitaraman A; Hung HT; Cheok CF; Goh BC
Nat Commun; 2020 Apr; 11(1):2086. PubMed ID: 32350249
[TBL] [Abstract][Full Text] [Related]
6. DNA sensing in cancer: Pro-tumour and anti-tumour functions of cGAS-STING signalling.
Wheeler OPG; Unterholzner L
Essays Biochem; 2023 Sep; 67(6):905-918. PubMed ID: 37534795
[TBL] [Abstract][Full Text] [Related]
7. Gain of function mutant p53 protein activates AKT through the Rac1 signaling to promote tumorigenesis.
Yue X; Wu F; Li Y; Liu J; Boateng M; Mandava K; Zhang C; Feng Z; Gao J; Hu W
Cell Cycle; 2020 Jun; 19(11):1338-1351. PubMed ID: 32275841
[TBL] [Abstract][Full Text] [Related]
8. Pontin, a new mutant p53-binding protein, promotes gain-of-function of mutant p53.
Zhao Y; Zhang C; Yue X; Li X; Liu J; Yu H; Belyi VA; Yang Q; Feng Z; Hu W
Cell Death Differ; 2015 Nov; 22(11):1824-36. PubMed ID: 25857266
[TBL] [Abstract][Full Text] [Related]
9. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
Ghaleb A; Padellan M; Marchenko N
Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
[TBL] [Abstract][Full Text] [Related]
10. DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation.
Lou M; Huang D; Zhou Z; Shi X; Wu M; Rui Y; Su J; Zheng W; Yu XF
J Med Virol; 2023 Jan; 95(1):e28310. PubMed ID: 36377393
[TBL] [Abstract][Full Text] [Related]
11. The cGAS Paradox: Contrasting Roles for cGAS-STING Pathway in Chromosomal Instability.
Hong C; Tijhuis AE; Foijer F
Cells; 2019 Oct; 8(10):. PubMed ID: 31658669
[TBL] [Abstract][Full Text] [Related]
12. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers.
Hong C; Schubert M; Tijhuis AE; Requesens M; Roorda M; van den Brink A; Ruiz LA; Bakker PL; van der Sluis T; Pieters W; Chen M; Wardenaar R; van der Vegt B; Spierings DCJ; de Bruyn M; van Vugt MATM; Foijer F
Nature; 2022 Jul; 607(7918):366-373. PubMed ID: 35705809
[TBL] [Abstract][Full Text] [Related]
13.
Pan M; Jiang C; Tse P; Achacoso N; Alexeeff S; Solorzano AV; Chung E; Hu W; Truong TG; Arora A; Sundaresan T; Suga JM; Thomas S; Habel LA
J Clin Oncol; 2022 Jan; 40(2):171-179. PubMed ID: 34843402
[TBL] [Abstract][Full Text] [Related]
14. BAG2 promotes tumorigenesis through enhancing mutant p53 protein levels and function.
Yue X; Zhao Y; Liu J; Zhang C; Yu H; Wang J; Zheng T; Liu L; Li J; Feng Z; Hu W
Elife; 2015 Aug; 4():. PubMed ID: 26271008
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.
Kang HJ; Chun SM; Kim KR; Sohn I; Sung CO
PLoS One; 2013; 8(8):e72609. PubMed ID: 23967324
[TBL] [Abstract][Full Text] [Related]
16. Tumour-associated mutant p53 drives the Warburg effect.
Zhang C; Liu J; Liang Y; Wu R; Zhao Y; Hong X; Lin M; Yu H; Liu L; Levine AJ; Hu W; Feng Z
Nat Commun; 2013; 4():2935. PubMed ID: 24343302
[TBL] [Abstract][Full Text] [Related]
17. Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.
Tanaka N; Zhao M; Tang L; Patel AA; Xi Q; Van HT; Takahashi H; Osman AA; Zhang J; Wang J; Myers JN; Zhou G
Oncogene; 2018 Mar; 37(10):1279-1292. PubMed ID: 29269868
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53 gains new function in promoting inflammatory signals by repression of the secreted interleukin-1 receptor antagonist.
Ubertini V; Norelli G; D'Arcangelo D; Gurtner A; Cesareo E; Baldari S; Gentileschi MP; Piaggio G; Nisticò P; Soddu S; Facchiano A; Bossi G
Oncogene; 2015 May; 34(19):2493-504. PubMed ID: 24998848
[TBL] [Abstract][Full Text] [Related]
19. The activating transcription factor 3 protein suppresses the oncogenic function of mutant p53 proteins.
Wei S; Wang H; Lu C; Malmut S; Zhang J; Ren S; Yu G; Wang W; Tang DD; Yan C
J Biol Chem; 2014 Mar; 289(13):8947-59. PubMed ID: 24554706
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 leads to low-grade IFN-I-induced inflammation and impairs cGAS-STING signalling in mice.
Qin Z; Liu H; Sheng Q; Dan J; Wu X; Li H; Wang L; Zhang S; Yuan C; Yuan H; Wang H; Zhou R; Luo Y; Xie X
Eur J Immunol; 2023 Sep; 53(9):e2250211. PubMed ID: 37377275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
